FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215945360> ?p ?o ?g. }

• W3215945360 endingPage "108429" @default.
• W3215945360 startingPage "108429" @default.
• W3215945360 abstract "The efficacy and safety of cenobamate relative to other antiseizure medications (ASMs) has not been evaluated. An indirect treatment comparison (network meta-analysis) was performed to determine if adjunctive cenobamate increases the odds ratio (OR) for ≥50% responder rate or for withdrawals due to treatment-emergent adverse events (TEAEs) leading to ASM discontinuation versus adjunctive therapy with other ASMs.A systematic literature review was conducted to identify randomized, double-blind, placebo-controlled trials (maintenance phase ≥ 12 weeks) assessing adjunctive ASMs in adults with uncontrolled focal seizures. Cenobamate was compared to a group of seven other ASMs, and to subgroups of branded (brivaracetam, eslicarbazepine acetate, lacosamide, and perampanel) and older (lamotrigine, levetiracetam, and topiramate) ASMs at FDA-recommended daily maintenance doses (FDA-RDMD), at all doses, and at maximum and minimum daily doses. Statistical significance was set at p < 0.05.Twenty-one studies were eligible for analysis. The placebo-adjusted ≥ 50% responder rate for FDA-RDMD of cenobamate was superior (OR 4.200; 95% CI 2.279, 7.742) to FDA-RDMD of all seven assessed (OR 2.202 95% CI 1.915, 2.532; p = 0.044) and branded ASMs (OR 2.148; 95% CI 1.849, 2.494; p = 0.037). There was no significant difference for ≥50% responder rate between FDA-RDMD of cenobamate and FDA-RDMD of older ASMs (OR 2.617; 95% CI 1.767, 3.878; p = 0.202). No significant differences were identified for ≥50% responder rate when comparing all doses and maximum/minimum doses of cenobamate to all seven, branded, and older ASMs. Cenobamate demonstrated comparable TEAE withdrawal rates to all seven ASMs, branded ASMs, and older ASMs across each of the four dose ranges (all p > 0.05).Patients receiving FDA-RDMD of cenobamate were more likely to have ≥50% seizure reduction compared with FDA-RDMD of the seven assessed ASMs and branded ASMs, without an increase in treatment discontinuation due to TEAEs." @default.
• W3215945360 created "2021-12-06" @default.
• W3215945360 creator A5017045441 @default.
• W3215945360 creator A5028436742 @default.
• W3215945360 creator A5065830650 @default.
• W3215945360 date "2022-01-01" @default.
• W3215945360 modified "2023-09-30" @default.
• W3215945360 title "Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures" @default.
• W3215945360 cites W1498758291 @default.
• W3215945360 cites W1551373999 @default.
• W3215945360 cites W1857985470 @default.
• W3215945360 cites W1916788136 @default.
• W3215945360 cites W1970608368 @default.
• W3215945360 cites W1974098973 @default.
• W3215945360 cites W1976810263 @default.
• W3215945360 cites W1978285852 @default.
• W3215945360 cites W1979558709 @default.
• W3215945360 cites W1984234523 @default.
• W3215945360 cites W1992028227 @default.
• W3215945360 cites W2025490080 @default.
• W3215945360 cites W2033585778 @default.
• W3215945360 cites W2041090550 @default.
• W3215945360 cites W2042774009 @default.
• W3215945360 cites W2051013481 @default.
• W3215945360 cites W2082045121 @default.
• W3215945360 cites W2084160703 @default.
• W3215945360 cites W2112789502 @default.
• W3215945360 cites W2125776201 @default.
• W3215945360 cites W2135808877 @default.
• W3215945360 cites W2157823046 @default.
• W3215945360 cites W2163886527 @default.
• W3215945360 cites W2171332093 @default.
• W3215945360 cites W2394852456 @default.
• W3215945360 cites W2522740415 @default.
• W3215945360 cites W2804818204 @default.
• W3215945360 cites W2806669859 @default.
• W3215945360 cites W2988342087 @default.
• W3215945360 cites W3012636246 @default.
• W3215945360 cites W3022995359 @default.
• W3215945360 cites W3025465714 @default.
• W3215945360 cites W3025691036 @default.
• W3215945360 cites W3123827906 @default.
• W3215945360 cites W4253837878 @default.
• W3215945360 cites W3023496243 @default.
• W3215945360 doi "https://doi.org/10.1016/j.yebeh.2021.108429" @default.
• W3215945360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34864380" @default.
• W3215945360 hasPublicationYear "2022" @default.
• W3215945360 type Work @default.
• W3215945360 sameAs 3215945360 @default.
• W3215945360 citedByCount "8" @default.
• W3215945360 countsByYear W32159453602022 @default.
• W3215945360 countsByYear W32159453602023 @default.
• W3215945360 crossrefType "journal-article" @default.
• W3215945360 hasAuthorship W3215945360A5017045441 @default.
• W3215945360 hasAuthorship W3215945360A5028436742 @default.
• W3215945360 hasAuthorship W3215945360A5065830650 @default.
• W3215945360 hasBestOaLocation W32159453601 @default.
• W3215945360 hasConcept C118552586 @default.
• W3215945360 hasConcept C126322002 @default.
• W3215945360 hasConcept C142724271 @default.
• W3215945360 hasConcept C168563851 @default.
• W3215945360 hasConcept C197934379 @default.
• W3215945360 hasConcept C204787440 @default.
• W3215945360 hasConcept C27081682 @default.
• W3215945360 hasConcept C2777332695 @default.
• W3215945360 hasConcept C2777683783 @default.
• W3215945360 hasConcept C2778139780 @default.
• W3215945360 hasConcept C2778186239 @default.
• W3215945360 hasConcept C2778715236 @default.
• W3215945360 hasConcept C2778802184 @default.
• W3215945360 hasConcept C2780836401 @default.
• W3215945360 hasConcept C3018162438 @default.
• W3215945360 hasConcept C42219234 @default.
• W3215945360 hasConcept C44249647 @default.
• W3215945360 hasConcept C71924100 @default.
• W3215945360 hasConceptScore W3215945360C118552586 @default.
• W3215945360 hasConceptScore W3215945360C126322002 @default.
• W3215945360 hasConceptScore W3215945360C142724271 @default.
• W3215945360 hasConceptScore W3215945360C168563851 @default.
• W3215945360 hasConceptScore W3215945360C197934379 @default.
• W3215945360 hasConceptScore W3215945360C204787440 @default.
• W3215945360 hasConceptScore W3215945360C27081682 @default.
• W3215945360 hasConceptScore W3215945360C2777332695 @default.
• W3215945360 hasConceptScore W3215945360C2777683783 @default.
• W3215945360 hasConceptScore W3215945360C2778139780 @default.
• W3215945360 hasConceptScore W3215945360C2778186239 @default.
• W3215945360 hasConceptScore W3215945360C2778715236 @default.
• W3215945360 hasConceptScore W3215945360C2778802184 @default.
• W3215945360 hasConceptScore W3215945360C2780836401 @default.
• W3215945360 hasConceptScore W3215945360C3018162438 @default.
• W3215945360 hasConceptScore W3215945360C42219234 @default.
• W3215945360 hasConceptScore W3215945360C44249647 @default.
• W3215945360 hasConceptScore W3215945360C71924100 @default.
• W3215945360 hasLocation W32159453601 @default.
• W3215945360 hasLocation W32159453602 @default.
• W3215945360 hasOpenAccess W3215945360 @default.
• W3215945360 hasPrimaryLocation W32159453601 @default.
• W3215945360 hasRelatedWork W18984091 @default.

• next